171347-89-0

Basic information

• Product Name: tert-butyl ((S)-3-(1H-indol-3-yl)-1-oxo-1-(((S)-1-phenylethyl)amino)propan-2-yl)carbamate
• Synonyms: tert-butyl ((S)-3-(1H-indol-3-yl)-1-oxo-1-(((S)-1-phenylethyl)amino)propan-2-yl)carbamate
• CAS NO: 171347-89-0
• Molecular Weight: 407.513
• Mol File: 171347-89-0.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl ((S)-3-(1H-indol-3-yl)-1-oxo-1-(((S)-1-phenylethyl)amino)propan-2-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl ((S)-3-(1H-indol-3-yl)-1-oxo-1-(((S)-1-phenylethyl)amino)propan-2-yl)carbamate(171347-89-0)
• EPA Substance Registry System: tert-butyl ((S)-3-(1H-indol-3-yl)-1-oxo-1-(((S)-1-phenylethyl)amino)propan-2-yl)carbamate(171347-89-0)

Safety Data

• Hazardous Substances Data: 171347-89-0(Hazardous Substances Data)

Upstream product

• 2627-86-3 (S)-1-phenyl-ethylamine 
• 13139-14-5 Boc-Trp-OH 
• 73-22-3 L-Tryptophan 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 171483-46-8 N-(2R-2-methoxy-carbonylmethyl-4-methylpentanoyl)-L-tryptophan (S)-methylbenzyl amide 

Relevant articles and documents

Base-Promoted N-Pyridylation of Heteroarenes Using N-Propargyl Enaminones as Equivalents of Pyridine Scaffolds

N-Pyridylation of various N-heteroarenes, including N-heteroarene-containing peptides, was achieved using N-propargyl enaminones (isolated or generated in situ from propargyl amine and propynones) as masked polysubstituted pyridine cores. This metal-free

C ring may be dispensable for β-carboline: Design, synthesis, and bioactivities evaluation of tryptophan analog derivatives based on the biosynthesis of β-carboline alkaloids

According to our previous work and the latest research on the biosynthesis of β-carboline, and using the reverse thinking strategy, tryptophan, the biosynthesis precursor of β-carboline alkaloids, and their derivatives were synthesized, and their biological activities and structure-activity relationships were studied. This bioassay showed that these compounds exhibited good inhibitory activities against tobacco mosaic virus (TMV); especially (S)-2-amino-3-(1H-indol-3-yl)-N-octylpropanamide (4) (63.3 ± 2.1%, 67.1 ± 1.9%, 68.7 ± 1.3%, and 64.5 ± 3.1%, 500 μg/mL) exhibited the best antiviral activity both in vitro and in vivo. Compound 4 was chosen for the field trials and the acute oral toxicity test, the results showed that the compound exhibited good anti-TMV activity in the field and low acute oral toxicity. We also found that these compounds showed antifungal activities and insecticidal activities.

Matrix metalloproteinase inhibitors: A structure-activity study

Modifications around the dipeptide-mimetic core of a hydroxamic acid based matrix metalloproteinase inhibitor were studied. These variations incorporated a variety of natural, unnatural, and synthetic amino acids inaddition to modifications of the P1' and P3' substituents. The results of this study indicate the following structural requirements: (2) Potent inhibitorsmust possess string zinc-binding functionalities. (3) The potential importance of the hydrophobic group at position R3 as illustratedby itsability to impart greater relative potency against stromelysin when larger hydrophobic groups are used. (4) Requirements surrounding the nature of the amino acid appear to be more restrictive for stromelysin than for neutrophil collagenase, 72 kDa gelatinase, and 92 kDa gelatinase. These requirements may involve planar fused-ring aryl systems and possibly hydrogen-bonding capabilities.